Authors:
Zisman, A
Ng, CP
Pantuck, AJ
Bonavida, B
Belldegrun, AS
Citation: A. Zisman et al., Actinomycin D and gemcitabine synergistically sensitize androgen-independent prostate cancer cells to Apo2L/TRAIL-mediated apoptosis, J IMMUNOTH, 24(6), 2001, pp. 459-471
Authors:
Chao, D
Zisman, A
Freedland, SJ
Pantuck, AJ
Said, JW
Belldegrun, AS
Citation: D. Chao et al., Sarcomatoid renal cell carcinoma: basic biology, clinical behavior and response to therapy, UROL ONCOL, 6(6), 2001, pp. 231-238
Authors:
Belldegrun, A
Tso, CL
Zisman, A
Naitoh, J
Said, J
Pantuck, AJ
Hinkel, A
de Kernion, J
Figlin, R
Citation: A. Belldegrun et al., Interleukin 2 gene therapy for prostate cancer: Phase I clinical trial andbasic biology, HUM GENE TH, 12(8), 2001, pp. 883-892
Authors:
Zisman, A
Pantuck, AJ
Dorey, F
Said, JW
Shvarts, O
Quintana, D
Gitlitz, BJ
deKernion, JB
Figlin, RA
Belldegrun, AS
Citation: A. Zisman et al., Improved prognostication of renal cell carcinoma using an integrated staging system, J CL ONCOL, 19(6), 2001, pp. 1649-1657
Authors:
Zisman, A
Pantuck, AJ
Figlin, RA
Belldegrun, AS
Citation: A. Zisman et al., Validation of the UCLA integrated staging system for patients with renal cell carcinoma, J CL ONCOL, 19(17), 2001, pp. 3792-3793
Authors:
Pantuck, AJ
Zisman, A
Henderson, D
Wilson, D
Schreiber, A
Belldegrun, A
Citation: Aj. Pantuck et al., New biologicals for prostate cancer prevention: Genes, vaccines, and immune-based interventions, UROLOGY, 57(4A), 2001, pp. 95-99
Authors:
Belldegrun, A
Bander, NH
Lerner, SP
Wood, DP
Pantuck, AJ
Citation: A. Belldegrun et al., Society of urologic oncology biotechnology forum: New approaches and targets for advanced prostate cancer, J UROL, 166(4), 2001, pp. 1316-1321
Authors:
Zisman, A
Pantuck, AJ
Chao, D
Dorey, F
Said, JW
Gitlitz, BJ
de Kernion, JB
Figlin, RA
Belldegrun, AS
Citation: A. Zisman et al., Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. Better correlates with clinicaloutcome, J UROL, 166(1), 2001, pp. 54-58
Citation: A. Zisman et al., Gene and immune-based therapies for genitourinary malignancies: Current status and future prospects, ISR MED ASS, 2(1), 2000, pp. 33-42
Authors:
Pantuck, AJ
Zismon, A
Tso, CL
Belldegrun, AS
Citation: Aj. Pantuck et al., Intermittent androgen deprivation therapy: schedule modifications based ona novel in vivo human xenograft model, PROSTATE C, 3(4), 2000, pp. 280-282
Citation: Aj. Pantuck et al., Gene therapy for prostate cancer at the University of California, Los Angeles: preliminary results and future directions, WORLD J URO, 18(2), 2000, pp. 143-147
Authors:
Perrotti, M
Han, KR
Epstein, RE
Kennedy, EC
Rabbani, F
Badani, K
Pantuck, AJ
Weiss, RE
Cummings, KB
Citation: M. Perrotti et al., Re: Prospective evaluation of endorectal magnetic resonance imaging to detect tumor foci in men with prior negative prostatic biopsy: A pilot study -Reply, J UROL, 163(6), 2000, pp. 1894-1894
Authors:
Pantuck, AJ
Han, KR
Perrotti, M
Weiss, RE
Cummings, KB
Citation: Aj. Pantuck et al., Ureteroenteric anastomosis in continent urinary diversion: Long-term results and complications of direct versus nonrefluxing techniques, J UROL, 163(2), 2000, pp. 450-455
Authors:
Perrotti, M
Han, KR
Epstein, RE
Kennedy, EC
Rabbani, F
Badani, K
Pantuck, AJ
Weiss, RE
Cummings, KB
Citation: M. Perrotti et al., Prospective evaluation of endorectal magnetic resonance imaging to detect tumor foci in men with prior negative prostatic biopsy: A pilot study, J UROL, 162(4), 1999, pp. 1314-1317
Authors:
Murphy, DP
Pantuck, AJ
Amenta, PS
Das, KM
Cummings, KB
Keeney, GL
Weiss, RE
Citation: Dp. Murphy et al., Female urethral adenocarcinoma: Immunohistochemical evidence of more than 1 tissue of origin, J UROL, 161(6), 1999, pp. 1881-1884